PRIMABS Trademark

Trademark Overview

On Tuesday, October 26, 2021, a trademark application was filed for PRIMABS with the United States Patent and Trademark Office. The USPTO has given the PRIMABS trademark a serial number of 97092356. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, November 5, 2024. This trademark is owned by EUTROPICS PHARMACEUTICALS, INC.. The PRIMABS trademark is filed in the Pharmaceutical Products category with the following description:

Predictive diagnostic anti body biomarker reagents for medical purposes, namely, for predictive diagnosis of cancer and immune disease
primabs

General Information

Serial Number97092356
Word MarkPRIMABS
Filing DateTuesday, October 26, 2021
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 26, 2024

Trademark Statements

Goods and ServicesPredictive diagnostic anti body biomarker reagents for medical purposes, namely, for predictive diagnosis of cancer and immune disease

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 9, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEUTROPICS PHARMACEUTICALS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02138

Trademark Events

Event DateEvent Description
Friday, October 29, 2021NEW APPLICATION ENTERED
Tuesday, November 9, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 3, 2022ASSIGNED TO EXAMINER
Friday, August 12, 2022NON-FINAL ACTION WRITTEN
Friday, August 12, 2022NON-FINAL ACTION E-MAILED
Friday, August 12, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 13, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 13, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 13, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 14, 2023SUSPENSION LETTER WRITTEN
Tuesday, March 14, 2023LETTER OF SUSPENSION E-MAILED
Tuesday, March 14, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, October 17, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, April 15, 2024ASSIGNED TO EXAMINER
Wednesday, April 17, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Wednesday, April 17, 2024NON-FINAL ACTION WRITTEN
Wednesday, April 17, 2024NON-FINAL ACTION E-MAILED
Wednesday, April 17, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, July 17, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, July 17, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, October 17, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 17, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 17, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 31, 2024APPROVED FOR PUB - PRINCIPAL REGISTER

Related Keywords

primabs predictive namely diagnosis cancer disease immune purposes medical diagnostic anti